SER 150

Drug Profile

SER 150

Alternative Names: EV 077; EV-077-3201-2; EV-077-3201-2TB; EV-077-3201-2TBS; SER 150 DN; SER 150 TBS

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evolva Biotech
  • Developer Evolva Holding SA; Serodus
  • Class Anticoagulants; Antivirals; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors; Thromboxane receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • No development reported Influenza A virus infections

Most Recent Events

  • 21 Dec 2016 Serodus completes a phase II trial in Diabetic nephropathies in Germany (PO) (EudraCT2014-003985-25)
  • 15 Dec 2016 Biomarkers information updated
  • 28 Nov 2016 SER 150 is still available for licensing (http://www.serodus.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top